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Abstract
We have studied the functional characteristics and clinical importance of the natural killer (NK) cytotoxicity of peripheral blood mononuclear cells (PBMNC) from patients with ulcerative colitis. Normal NK activity was observed in PBMNC from patients with inactive disease, but a pronounced decrease was found in those with active disease. Clinical change from active to inactive disease was associated with enhancement of the depressed NK activity. The impairment of NK cytotoxicity found in patients with active disese could not be ascribed to a deficient number of NK cells as the amounts of HNK-1+, CD16+ (Leu 11), and CD11b (OKM1) cells in PBMNC were within normal ranges. This defective cytotoxic PBMNC activity was normalised by short term (18 hour) incubation with recombinant interleukin 2 (rIL-2). Moreover, long term (5 day) incubation of these effector cells with rIL-2 induced strong cytotoxic activity against NK resistant and NK sensitive target cells in patients with active and inactive disease. We also found that both precursors and effectors of cytotoxic activity promoted by short term and long term incubation with rIL-2 of PBMNC from the patients showed the phenotype of NK cells (CD16+, CD3-). Taken together, these results show that active ulcerative colitis is associated with a defective function of NK cells that is found to be normal in the inactive stage of the disease. The possible pathogenic and therapeutic implications of these findings are discussed. Ulcerative colitis is a chronic systemic inflammatory disease affecting principally the mucosa of the rectum and colon, with a clinical evolution characterised by remissions and exacerbations. The aetiology of this disease remains unknown, but it has been suggested that infectious agents might be involved in the induction of the colonic lesion.' " A possible pathogenic role of the immune system has also been proposed. 14 2021 We have investigated the functional characteristics and the clinical importance of the NK activity of PBMNC from patients with ulcerative colitis. years. When the experimental study was performed 14 patients had been taking steroids plus sulphasalazine for at least three weeks. At the time of the study the remaining 34 patients had not taken steroids for at least three months. Of these, 28 were taking sulphasalazine and six were receiving no specific treatment. First, the NK cytotoxic activity of PBMNC from patients with ulcerative colitis was analysed. As Table I illustrates, PBMNC from these patients show a clearly impaired NK cytotoxicity when compared with those of healthy control subjects (p<001). Next, we investigated separately the NK activity of PBMNC from ulcerative colitis patients with active and inactive disease. Impairment of cytotoxic activity was evident in patients with active disease, being significantly depressed compared with both patients with inactive disease and healthy control subjects (p<001) (Fig 1) . However, there were no significant differences in the NK activity ofPBMNC from patients with inactive disease when compared with healthy controls (p>005). Interestingly, the NK cytotoxicity of PBMNC from patients with active ulcerative colitis who were taking steroids overlapped with that of patients who were not (p>005).
Methods
We also investigated the possible variations in NK activity occurring in PBMNC from ulcerative colitis patients who progress from active to inactive disease. The depressed NK activity found in PBMNC from patients with active disease (mean (SD) 11 (4)% of specific lysis at a 50:1 effector to target cell ratio in six patients) was significantly enhanced (p<001) when the disease became inactive (30 (6))% of specific lysis at a 50:1 effector to target cell ratio). This increase in NK cytotoxicity was also found in one inactive patient who remained on steroid treatment (data not shown).
Quantitative flow cytometry studies were performed simultaneously to ascertain the number of phenotypically defined NK cells (Table II) . The percentages of CD16+ and HNK-1+ cells were similar in PBMNC samples from patients with either low or normal NK cytotoxic levels and from healthy control subjects (p>005). The numbers of cells bearing CD1lb, a surface heterodimer shared by NK cells and monocytic lineages, were also similar in the three groups of subjects (p>005). Consequently, patients with active ulcerative colitis had quantitatively normal but functionally defective NK cells in PBMNC.
IL-2 NORMALISES THE IMPAIRED FUNCTIONAL ACTIVITY OF NK CELLS
It has been shown that short term incubation with IL-2 can enhance the cytotoxic activity of normal NK cells. Along these lines, we tested the effect of titrated amounts of rIL-2 on the NK cytotoxicity of PBMNC from patients after 18 hours ofincubation. In a dose dependent manner, IL-2 enhanced the NK activity of patients with inactive disease and also increased and normalised the defective NK activity of patients with active disease (Fig 2) .
It could be argued that the cytotoxicity promoted by rIL-2 against K-562 found in PBMNC from three patients with active disease and three patients with inactive disease and three control subjects were left untreated (a) or were treated with anti-CD3 (CD3-, CD16') or anti-CD16 (CD3+, CD16-) monoclonal antibodies plus complement (b). 2 x 106 cells/ml were incubated in the presence of 100 IU/ml rIL-2 for 18 hours. At the end of the culture period, aliquots of untreated PBMNC were treated with anti-CD3 (CD3-CD16+) or anti-CD16 (CD3+, CD16-) monoclonal antibodies plus complement (c). Cultured cells were used as effectors against "Cr-labelled K-562 target cells at a 25:1 effector to target ratio. The results are expressed as the mean specific lysis of triplicate experiments performed with the different cellular subpopulations studied in each group of subjects. 
